Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
The bevacizumab biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant, can be used for ELISA, neutralization, in vitro and in vivo functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab. The research grade bevacizumab biosimilar protein, L234A L235A P329G (LALAPG) Fc silent mutant, is for research use only.
Synonyms: VEGF, VEGF-A, vascular endothelial growth factor A, anti-VEGF
产品参数
| 货号 | C001P-AAG |
|---|---|
| 产品名称 | Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 同种型 | Human IgG1 kappa. |
| 来源 | The anti-human VEGF-A monoclonal antibody Bevacizumab biosimilar with the Fc silent mutation by L234A L235A P329G (LALAPG) was produced in mammalian cells. |
| 特异性 | The in vivo grade Bevacizumab biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant specifically binds to the human VEGF-A. |
| 抗体形式 | 0.2 uM filtered solution, pH 6.2, no stabilizers or preservatives. |
| 内毒素 | < 0.1 EU per 1 ug of the protein by the LAL method. |
| 纯度 | >95% by SDS-PAGE under reducing conditions and HPLC. |
| 运输 | The recombinant monoclonal antibody Bevacizumab L234A L235A P329G (LALAPG) Fc silent mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| 稳定性与存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| 注意事项 | Bevacizumab biosimilar CHO stable cell line is available for licensing to manufacture the bevacizumab biosimilar protein. The research grade bevacizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
文献
C001P-AAG: Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Background
Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.